Abstract DM (diabetes mellitus) is present in 20-40 % of patients with liver cirrhosis, but its prognostic impact is unclear. Therefore, in the present study, we investigated whether the presence of DM in patients with cirrhosis was associated with increased mortality, and/or with increased incidence of SBP (spontaneous bacterial peritonitis). We reviewed medical and laboratory data of 230 patients with cirrhosis from the period 2001-2011, for whom data were complete in n = 226. Follow-up for the outcomes mortality and SBP was performed until May 2012, with only 13 patients lost to follow-up. DM was present at baseline in 78 patients (35 %). Median follow-up was 6.2 (interquartile range, 3.1-9.3) years, during which 118 patients died [47 out of 78 with DM (60 %), and 71 out of 148 without DM (48 %)]. The presence of DM at baseline was not associated with increased mortality after adjustment for age {HR (hazard ratio), 1.00 [95 % CI (confidence interval), 0.67-1.50]}. Further adjustment for sex, aetiology of cirrhosis, platelet count and the Child-Pugh or MELD (model for end-stage liver disease) score did not change this finding. During follow-up, 37 patients developed incident SBP (19 with DM and 18 without DM). DM at baseline was associated with incident SBP , even after adjustment for age, sex, aetiology, platelet count and the Child-Pugh [HR, 2.39 (95 % CI,)] or MELD score [HR, 2.50 (95 % CI,]. In conclusion, the presence of DM at baseline in patients with cirrhosis was associated with an increased risk of SBP , which may represent an increased susceptibility to infections. On the other hand, DM was not clearly associated with increased mortality in these patients.
INTRODUCTION
DM (diabetes mellitus) is a common comorbidity in patients with liver cirrhosis. Several studies have reported a prevalence of 20-40 % for DM in cirrhosis [1] [2] [3] [4] [5] , depending on the aetiology and severity of cirrhosis, and the diagnostic criteria used. We have recently shown that cirrhosis itself was independently associated Abbreviations: ALP , alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CC, cryptogenic cirrhosis; CI, confidence interval; DM, diabetes mellitus; EASL, European Association for the Study of the Liver; GGT, γ -glutamyltransferase; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HR, hazard ratio; HRS, hepatorenal syndrome; IGT, impaired glucose tolerance; INR, international normalized ratio; MELD, model for end-stage liver disease; NASH, non-alcoholic steatohepatitis; NGM, normal glucose metabolism; PMN, polymorphonuclear; SBP , spontaneous bacterial peritonitis.
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with DM {OR (odds ratio), 13.6 [95 % CI (confidence interval), 4.3-42.9]} in a cross-sectional study, and that the increased prevalence of DM in cirrhosis was not attributable to classical risk factors for DM, such as age, obesity, or a family history of DM [3] .
The prognostic impact of DM in patients with cirrhosis is currently unclear, although some studies have suggested that DM may be a risk factor for overall mortality. In the largest retrospective cohort study, with a median follow-up of 5 years, DM was associated with increased mortality [6] , but not when the presence of oesophageal varices was included as a covariate in a subgroup of 271 patients. Two small studies have also shown that DM was associated with increased 1-year [7] and 2-year mortality [8] . In contrast, in two other prospective studies, DM did not influence the prognosis [1] , or was no longer significantly associated with 2-year mortality after adjustment for Child-Pugh score and serum creatine [9] . These studies generally consisted of a small sample of patients (n < 100) [1, 7, 8] , had a low number of events (n = <20) [1, 7, 9] and/or included patients with longstanding cirrhosis at baseline [6, 9] .
The presence of DM may predispose to serious bacterial infections, as has been reported in patients with Type 2 DM in general [10, 11] . Moreover, patients with cirrhosis are characterized by immune dysfunction, which makes them highly susceptible to a variety of (bacterial) infections such as respiratory tract infections, urinary tract infections, sepsis and SBP (spontaneous bacterial peritonitis) [12] . Hence, bacterial infections were reported to be present at admission or developed during hospitalization in about 30 % of patients with cirrhosis [13] . Such infections are one of the most common causes of death in patients with cirrhosis, leading to a four-fold increased mortality [14] . Currently, only a higher Child-Pugh score [or MELD (model for end-stage liver disease) score] is an established risk factor for infections [12, 15] . Whether the presence of DM in patients with cirrhosis further increases the risk of infections, is as yet unclear, although the prevalence of bacteriuria was higher in patients with DM compared with those without [16] .
For these reasons, we investigated, in a relatively large cohort (n > 100), whether the presence of DM at diagnosis of cirrhosis was associated with increased overall mortality and liver-related mortality. In addition, we investigated whether DM was associated with incident SBP, a common and serious infection in patients with cirrhosis [13, 17] that could be reliably retrieved and defined in our study.
MATERIALS AND METHODS

Subjects and study design
We conducted a retrospective observational study on a cohort of patients diagnosed with liver cirrhosis. Patients were selected by searching our digital diagnosis-treatment combination registry for codes 'compensated liver cirrhosis' and 'decompensated liver cirrhosis'. We selected all patients treated for cirrhosis at our hospital from January 2001 to December 2011. The diagnosis of liver cirrhosis was based on liver biopsy, or on the combination of clinical signs, biochemical abnormalities, radiological findings (small, nodular liver and splenomegaly) and the presence of oesophageal varices or portal gastropathy on endoscopy. All patients were evaluated for the presence of Hepatitis B and C antibodies. In subjects without excessive alcohol consumption ( 2 units/day for women, 3 units/day for men), cirrhosis was called 'cryptogenic' when an additional extensive evaluation yielded no specific aetiology. The study protocol was approved by the Medical Ethical Committee of Catharina Hospital.
Baseline data collection and definitions
All data were collected from the medical files and the (digital) laboratory information system. The first day of admission to, or the first contact at the out-patient clinic of, our hospital was used as baseline. Data collected at this time were age, sex, current alcohol consumption, a history of DM, aetiology of cirrhosis, presence of ascites and presence of HE (hepatic encephalopathy). Alcohol consumption was categorized into low (<1 unit/day), moderate (1-2 units/day for women, 1-3 units/day for men) and excessive alcohol consumption (>2 units/day for women, and >3 units/day for men). Aetiology of cirrhosis was categorized as alcoholic, viral, autoimmune and cryptogenic, with patients with cirrhosis after NASH (non-alcoholic steatohepatitis) grouped together with patients with CC (cryptogenic cirrhosis), since several patients with CC may have had NASH before [18, 19] . Patients with proven viral hepatitis and concomitant excessive alcohol consumption were classified as having viral cirrhosis. Standard laboratory methods were used to measure haemoglobin, platelet count (CELL-DYN 4000; Abbott), non-fasting blood glucose, AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), GGT (γ -glutamyltransferase), total bilirubin, albumin, creatine (Siemens Advia 1650) and INR (international normalized ratio) (Roche) in all patients at the first contact.
The presence of DM at baseline, that is at the time of diagnosis of cirrhosis, was defined as a history of diagnosed DM (with or without medication), a random blood glucose >11.1 mmol/l together with symptoms, or two fasting blood glucose levels >6.9 mmol/l [20] . Owing to frequent changes in therapy, we recorded the type of treatment most recently initiated for DM, categorized into no medical treatment, oral antihyperglycaemic agents or insulin. The severity of liver cirrhosis was classified using the Child-Pugh score [21, 22] , and the MELD score based on bilirubin, creatine and INR [22, 23] .
Follow-up and mortality
Follow-up of patients was performed until May 2012. We reviewed (digital) medical files of all specialities in our hospital from the diagnosis of cirrhosis until death or until the last visit to our hospital to any speciality. In the case of death, date and cause of death were retrieved from the medical files and death certificates wherever possible. Liver-related death was defined as death due to (a combination of) liver failure, HE, combined liver/kidney failure, sepsis, SBP or HCC (hepatocellular carcinoma). In patients who were still alive in the previous year (May 2011 to May 2012) according to our records, the last visit to our hospital was taken as last date of follow-up. When patients had neither died, according to our records, nor visited our hospital in the previous year (May 2011 to May 2012), we contacted their general practitioners to inquire about their present status.
Incident SBP and DM
We reviewed all medical files, radiological examinations and laboratory measurements for development of the first SBP during follow up. Diagnostic paracentesis was performed in all patients with cirrhosis and ascites at hospital admission, and in patients with signs of systemic infection, abdominal symptoms or acute kidney injury/liver failure. When ascitic PMN (polymorphonuclear) count was 250 cells/mm 3 , SBP was considered positive, and the patient was treated accordingly with intravenous antibiotics regardless of culture results, according to EASL (European Association for the Study of the Liver) guidelines [17] . Patients with a PMN count <250/mm 3 , but positive ascitic cultures, together with signs of systemic infection/inflammation and/or abdominal symptoms were also treated with intravenous antibiotics, in agreement with the EASL guidelines [17] . Asymptomatic patients with positive ascitic cultures but without signs of infection or progressive renal/liver failure were considered SBP-free, were not treated with antibiotics, and were followed up clinically and/or by repeated paracentesis. The first date of admission for SBP was taken for (event-free) survival analyses. Owing to high resistance of gut flora against quinolones (40 % of Escherichia coli quinolone-resistant) in our hospital/region, patients in our hospital did not receive primary antibiotic prophylaxis during the study period. In case patients experienced multiple episodes of SBP, the (time to the) first episode was taken for survival analyses. Recurrent SBP was also documented. Incident DM during follow-up at our hospital was defined using the definitions described above.
Statistical analysis
General characteristics of the study population at baseline were compared between patients with and without DM at baseline using independent Student's t test or Mann-Whitney U test for continuous variables, and a χ 2 test for discrete variables. Associations between baseline DM and the three outcomes that is overall mortality, liver-related mortality and incident SBP, were investigated with Kaplan-Meier curves and log rank tests. In addition, Cox proportional hazard regression models were used to investigate the influence of potential confounders on the associations between DM and outcomes, with adjustment for age, sex, cirrhosis aetiology (alcoholic, cryptogenic, viral, autoimmune), platelet count and severity of cirrhosis (continuous Child-Pugh or MELD score).
In an additional analysis, we investigated whether any of the main associations reported differed between sexes, severity of cirrhosis and cirrhosis aetiology by adding interaction terms between DM and sex, Child-Pugh score, MELD score or cirrhosis aetiology respectively to the (fully adjusted) models. A two-sided P-value of <0.05 was considered statistically significant. All analyses were performed using the Statistical Package for Social Sciences for Windows, version 17.0 (SPSS).
RESULTS
Study population and baseline characteristics
We included 230 patients from the period 2001-2011, for whom data were complete in n = 226. Cirrhosis was proven by liver biopsy in 29 % of patients. The aetiology of cirrhosis was mainly alcohol abuse (61 %), followed by cryptogenic/NASH cirrhosis (21 %), viral cirrhosis (11 %) and autoimmune liver diseases (4 %). In eight patients (4 %), cirrhosis was due to other causes such as medication (n = 6), α1-antitrypsin deficiency (n = 1), or hereditary haemochromatosis (n = 1). At inclusion in the present study, cirrhosis was newly diagnosed in 206 patients (91 %), and already known for 1-5 years in 20 patients.
DM was present at baseline in 78 patients (35 %), of whom 17 were newly diagnosed. A total of 16 patients (21 %) received no medical treatment, 19 (24 %) received oral anti-hyperglycaemic agents and 43 were treated with insulin (55 %). Baseline characteristics of patients with and without DM are shown in Table 1 . Patients with DM were older, and had a higher non-fasting glucose on admission compared with patients without DM. Aetiology of cirrhosis was more often NASH/cryptogenic in patients with DM, and predominantly alcoholic in patients without DM. In addition, patients with DM had generally less elevated liver enzymes compared with patients without DM, which could be attributed to the difference in alcohol (ab)use. However, the Child-Pugh and MELD scores were not different between the two groups.
Mortality
Follow-up was performed until May 2012, with 190 patients (84 %) followed solely at our hospital, 23 (10 %) followed by general practitioners in the end and only 13 patients lost to followup (5.8 %; two with DM, 11 without DM). Median follow up was 6.2 (interquartile range, 3.1-9.3) years, during which 118 patients died (47 out of the 78 with DM (60 %) and 71 out of the 148 without DM (48 %). Causes of death were classified as liver-related in 80 cases (Table 2) . Median survival was 4.2 (95 % CI, 2.5-5.8) years for patients with DM and 7.2 (95 % CI, 4.5-9.9) years for patients without DM at baseline (P = 0.050). DM seemed to be associated with overall mortality in a crude analysis [HR (hazard ratio), 1.45 (95 % CI, 1.00-2.10)], but this effect was completely attenuated after adjustment for age [HR, 1.00 (95 % CI, 0.67-1.50)] ( 
SBP
During the follow-up period, 37 patients were admitted to our hospital with incident SBP (19 with DM and 18 without DM). SBP diagnosis was established on elevated ascitic PMN count in 26 cases (70 %), and based on positive cultures together with signs of systemic infection and/or acute liver/kidney failure in the remaining 11 patients (no differences between patients with or without DM, P = 0.800). Altogether, a microbiological agent was found in 22 cases (59 %) of SBP. The presence of DM was significantly associated with a higher incidence of SBP (Figure 1 ; P = 0.007). DM was associated with incident SBP in a crude regression analysis [HR, 2.39 (95 % CI, 1.24-4.60)], and also in fully adjusted models including age, sex, aetiology, platelet count and Child-Pugh [HR, 2.39 (95 % CI, 1.10-5.18)] or MELD score [HR, 2.50 (95 % CI, 1.16-5.40)] respectively (Table 4 ). Of note, 22 episodes of SBP (59 %) were either on admission at the time cirrhosis was diagnosed (n = 9) or within 2 months of admission to our hospital (n = 13), as can be derived from Figure 1 . On admission, 12 out of these 22 patients had DM, compared with seven out of 15 patients that developed an SBP >2 months after diagnosis of cirrhosis had been established (P = 0.638). As such, DM at baseline was associated with a higher incidence of SBP both early after diagnosis of cirrhosis had been established, and also more than 2 months after diagnosis of cirrhosis. Only three patients in our cohort [one with auto-immune cirrhosis (primary biliary sclerosis), one with alcoholic cirrhosis and one patient with cirrhosis due to hepatitis C and alcohol] developed a second SBP (one with DM and two without DM at baseline (and also without DM at follow-up), P = 1.00). Only the patient with alcoholic cirrhosis received secondary SBP prophylaxis after his first SBP (trimethoprim-sulfamethoxazole 960 mg daily) for a few days, but soon discontinued this after resuming alcohol consumption.
Incident DM
During follow-up, 23 out of 148 patients (16 %) without DM at baseline developed de novo DM. The remaining 125 patients Table 3 Cox-regression analysis of the effect of DM on mortality Fully adjusted associations between DM and mortality were adjusted for age, sex, aetiology, platelet count and the Child-Pugh score or MELD score respectively. without DM at baseline were not structurally tested for DM, but at least had not developed clinical DM during follow-up at our hospital. The development of incident DM may attenuate, over time, the associations of DM at baseline with mortality and incident SBP. However, appreciation of (fully adjusted) Coxregression models with a time-dependent variable (including an interaction term between diabetes at baseline and time) confirmed that the assumption of proportional hazards over time was not violated (all P interactions >0. 10) , and that the prognostic effect of DM did not change over time. In addition, either censoring patients at the time of incident DM (n = 23) or confining analyses to subjects only followed up at our hospital (n = 190) did not influence our results (results not shown).
In order to further investigate the effect of prevalent and incident DM on mortality and SBP, we conducted two analyses. . In summary, the results of these analyses comparing the group with DM at baseline with no DM at all during follow-up were similar to those comparing DM at baseline with no DM at baseline (consisting of subjects that may or may not develop DM during follow-up).
Additional analyses
We also investigated whether the prognostic effect of DM in patients with cirrhosis differed between sexes, severity of cirrhosis and cirrhosis aetiology. For (overall) mortality, we found no effect modification for sex, cirrhosis aetiology or MELD score (all P interaction>0.10). A borderline P value (P = 0.078) for interaction between DM and the continuous Child-Pugh score suggested that the prognostic effect of DM might be stronger in those with lower Child-Pugh scores. However, no significant interaction was found for Child-Pugh classes (P interaction = 0.340). With regard to SBP, no effect modification was observed for sex, cirrhosis aetiology, continuous Child-Pugh score or MELD score (all P interactions >0.10).
As described above, the majority of patients (91 %) was newly diagnosed with cirrhosis at inclusion in the present study, whereas 20 subjects were already known to have cirrhosis for 1-5 years. Therefore we also investigated potential differences between these groups and potential differences in the effect of DM on mortality and incident SBP. Patients with known cirrhosis (n = 206) and newly diagnosed cirrhosis (n = 20) had similar Child-Pugh score at baseline (7.2 + − 2.2 compared with 7.7 + − 2.1; P = 0.315), similar MELD score at baseline (11.6 + − 7. 
DISCUSSION
The present study had two main findings. First, the presence of DM at the time of diagnosis of cirrhosis was not independently associated with an increased mortality. On the other hand, the presence of DM at the time of diagnosis of cirrhosis was significantly associated with an increased incidence of SBP, a serious infection for which hospitalization is usually required. This association was independent of known classical risk factors in patients with cirrhosis.
The crude borderline significant difference in survival we observed between patients with and without DM could be completely attributed to the fact that patients with DM were on average 10 years older than those without DM. Our results partially agree with the only other large retrospective cohort study, performed between 1980 and 1991, in which a small effect of DM on 5-year survival was observed [HR, 1.18 (95 % CI, 1.03-1.37)] independent of age, platelet count and components of the Child-Pugh score [6] . However, DM was, in that study, neither associated with 3-year survival nor with 5-year survival in the subgroup of 271 patients with endoscopic data. As in our study, patients with DM had similar Child-Pugh scores compared with those without DM, but were significantly older. In agreement, two small prospective studies also observed that DM was not (independently) associated with mortality [1, 9] . Two studies showed that DM was associated with mortality independently of age [7, 8] , but these studies were relatively small and contained a selected sample of patients with severe (alcoholic) cirrhosis and (refractory) ascites. Most patients with cirrhosis die because of liver-related complications such as liver failure, HRS (hepatorenal syndrome), variceal bleeding, HE, HCC or SBP, as shown by our study and others [1, 6, 8] . The presence of hyperglycaemia and/or hyperinsulinaemia has been hypothesized to promote hepatitis and fibrosis, and accelerate the deterioration of liver function, hence leading to more liver-related deaths [24, 25] . In agreement with this theory, the degree of insulin resistance has been correlated to the degree of fibrosis in patients with chronic hepatitis C [26] , and the presence of DM was correlated with the degree of fibrosis in hereditary haemochromatosis [27] . However, in patients with cirrhosis (i.e. grade 4 fibrosis), the presence of DM has not been associated with a worse liver function, as indicated by Child-Pugh score or MELD score [6, 7, 9] , nor with an increase in liver-related mortality in our study. As such, hyperglycaemia and/or hyperinsulinaemia may have a role in the progression of chronic liver diseases to cirrhosis, but apparently do not affect liver function when end-stage liver disease has been reached.
An important novel finding of the present study is that the incidence of SBP was about two-fold higher in patients with DM at baseline compared with those without DM. No previous studies have investigated this before, but a few case-control studies on subjects with ascites did show higher rates of DM in patients with SBP compared with those with sterile ascites, although not always significant due to small sample sizes [15, 28, 29] . The observed association between DM and SBP may represent an increased susceptibility to (bacterial) infections in subjects with both cirrhosis and DM, in agreement with observations that DM was also associated with more respiratory and urinary tract infections in patients with cirrhosis [16, 30] . In addition, DM has recently been associated with SBP resistant to third-generation cephalosporins [31] , which could reflect previous courses of antibiotics that have been given to these patients for other infections. Remarkably, the presence of DM among patients with SBP was not associated with an increased mortality in this study, in agreement with the similar liver-related mortality (including SBP-related mortality) in patients with or without DM in our study. A potential explanation could be that patients with cirrhosis and DM are frequently monitored by gastroenterologists, internists, diabetes nurses and/or general practitioners, leading to rapid recognition of incident infections and adequate treatment.
When confirmed by other studies, our results might imply that DM in patients with cirrhosis is a marker to identify subjects at increased risk for bacterial infections who might benefit from antibiotic prophylaxis, in addition to subjects with gastrointestinal bleeding or ascites and advanced cirrhosis [32] . The observation that most episodes of SBP occurred within 2 months of diagnosis of cirrhosis might suggest that patients with cirrhosis who also have DM may be more prone to have or develop SBP, or infections in general, during admission, and should be monitored very closely. Anti-hyperglycaemic treatment may theoretically reduce the incidence of infections, but there have been no randomized controlled trials on treatment of DM in patients with cirrhosis. Only small observational studies suggest that good glycaemic control or treatment with metformin might be associated with decreased mortality [33, 34] . It should be noted that medical treatment of DM in patients with cirrhosis is not without risks, as the combination of reduced hepatic clearance and impaired glycogenolysis may increase the risk of severe hypoglycaemia in patients on oral anti-hyperglycaemic medication or insulin [24] . Therefore the potential benefits and harms of treatment of DM in patients with cirrhosis should be carefully considered in each individual patient.
The present study consisted of a relatively large sample of patients with cirrhosis with a wide range of Child-Pugh/MELD scores. We obtained complete baseline data and a median followup of 6 years for most of them, and only 13 patients were lost to follow-up. A major limitation of the study is its retrospective design which may lead to selection or information bias. However, all patients with cirrhosis must be coded with one of the used diagnosis-treatment combinations for financial purposes, and we have no reason to believe that patients with or without DM were differently registered. In addition, baseline data were structurally recorded for all patients as part of usual care, as were subsequent hospitalizations and mortality during follow-up. For these reasons, we feel that the retrospective design itself did not introduce considerable selection or information bias into the associations under investigation. However, we were unable to collect proper data on episodes of gastrointestinal bleeding, which is a risk factor for SBP [17, 32] . Although Child-Pugh score, MELD score, haemoglobin and platelet counts were comparable between patients with and without DM, and all patients with gastrointestinal bleeding received antibiotic prophylaxis (7 d), we can therefore not fully exclude residual confounding. In addition, given our observations regarding SBP, it would be interesting to investigate whether DM is also associated with several other bacterial infections, and with other cirrhosis-related complications, such as ascites, HRS, HE or HCC. However, the retrospective nature of our study precluded a prospective collection and proper definition of these complications (e.g. by regular creatine measurement, or psychometric testing for HE). Another potential limitation of our study is that we had no structural testing for incident DM, and we did not perform an OGTT (oral glucose tolerance test) at baseline to further classify NGM (normal glucose metabolism) or IGT (impaired glucose tolerance). This potential misclassification could explain the fact that we did not observe differences in mortality between patients with and without DM. However, several additional analyses allowing for incident DM yielded similar findings, and other studies have not (yet) observed differences in mortality between patients with NGM, IGT and DM [1, 7] .
In conclusion, we have shown that DM at the time of diagnosis of cirrhosis is an independent determinant of incident SBP in patients with cirrhosis. In agreement with other data on respiratory or urinary tract infections, the presence of DM may further increase the susceptibility for (bacterial) infections in patients with cirrhosis. On the other hand, this increased incidence of infections (in our case SBP) was not accompanied by an increased mortality in our study, although a prognostic effect of DM on mortality with HR <1.5 cannot be excluded. Anyway, the increased rate of bacterial infections in patients with DM probably leads to more frequent hospitalizations and (antibiotic) treatments, with considerable health care costs. Therefore it would be worthwhile to further investigate the role of DM in bacterial infections in patients with cirrhosis, and whether anti-hyperglycaemic treatment reduces the risk of bacterial infections, in particular those requiring hospitalization.
CLINICAL PERSPECTIVES
r DM is very common in patients with liver cirrhosis, and may increase mortality, either by accelerating deterioration of liver function, or by predisposing to serious infections, such as SBP.
r In the present study, the presence of DM at baseline was associated with incident SBP, which may represent an increased susceptibility to infections. On the other hand, we did not observe an independent association of DM with increased mortality.
r These results might imply that DM is a risk marker to identify patients at increased risk for infections, which should be monitored more closely, or perhaps benefit from antibiotic prophylaxis. Moreover, it would be interesting to investigate whether anti-hyperglycaemic treatment reduces the rate of infections.
